Anthony T. Reder to Young Adult
This is a "connection" page, showing publications Anthony T. Reder has written about Young Adult.
Connection Strength
0.224
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
Score: 0.081
-
4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology. 2009 Mar 24; 72(12):1100-1.
Score: 0.035
-
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
Score: 0.024
-
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
Score: 0.015
-
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
Score: 0.013
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
Score: 0.012
-
Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav. 2014 Feb; 31:77-84.
Score: 0.012
-
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
Score: 0.012
-
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
Score: 0.011
-
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
Score: 0.009